International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

Bruton's tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regarding the risk of cardiovascular (CV) adverse events, including atrial fibrillation (AF), hypertension, and heart failure. Newer BTKis appear to have lower CV risks, but data are limited. It is important to understand the risks posed by BTKis and how those risks interact with individual patients, and we convened a panel of physicians with expertise in CLL and CV toxicities in oncology to develop evidence-based consensus recommendations for community hematologists and oncologists. Care providers should thoroughly assess a patient's CV risk level before treatment initiation, including established CV diseases and risk factors, and perform investigations dependent on preexisting diseases and risk factors, including an electrocardiogram (ECG). For patients with high CV risk, BTKi treatment is often appropriate in consultation with a multidisciplinary team (MDT), and more selective BTKis, including acalabrutinib and zanubrutinib, are preferred. BTKi treatment should generally be avoided in patients with a history of heart failure. Ibrutinib should be avoided in patients with a history of ventricular arrhythmias, but the risk of newer drugs is not yet known. Finally, an MDT is crucial to help manage emerging toxicities with the goal of maintaining BTKi therapy, if possible. Optimizing heart failure, arrhythmia, and hypertension control will likely improve tolerance and maintenance of BTKi therapy. However, additional studies are needed to identify the most optimal strategy for these drugs.

Recuperação aguda da função ventricular sistólica após ajuste do intervalo atrioventricular / Acute recovery of systolic ventricular function after atrioventricular interval adjustment

Paciente do sexo masculino, com 85 anos de idade, portador de marcapasso dupla-câmara há 6 meses em decorrência de bradicardia sintomática, vem evoluindo com episódios de descompensação da insuficiênciacardíaca iniciados após o implante de marcapasso. Na última internação foi solicitada avaliação para realização deupgrade para terapia de ressincronização cardíaca. Após avaliação clínico-eletrocardiográfica triaxial, decidiu-se pelo ajuste do intervalo atrioventricular, pois apresentava bloqueio de ramo esquerdo induzido pela estimulação ventricular direita exclusiva com 120 ms de duração. O paciente evoluiu com melhora clínico-ecocardiográfica após prolongamento do intervalo atrioventricular de 200 ms para 300 ms, sem necessidade de implante de eletrodode ventrículo esquerdo...

Male, 85-year old patient, carrier of dual chamber pacemaker for 6 months due to symptomatic bradycardia is admitted with episodes of decompensated heart failure started after pacemaker implantation. In the last hospitalization an assessment for upgrade to cardiac resynchronization therapy was requested. After clinical and electrocardiographic triaxial evaluation we chose to perform an atrioventricular interval adjustment, since hepresented left bundle branch block induced by exclusive right ventricular stimulation with a duration of 120 ms.The patient evolved with clinical and echocardiographic improvement after prolonged atrioventricular intervalfrom 200 ms to 300 ms without the need for left ventricle lead implantation...

Amiloidose cardíaca: relato de caso / Cardiac amyloidosis: a case report

Relato de caso: paciente masculino, de 62 anos, hipertenso, procurou avaliação cardiológicapara risco cirúrgico de varicectomia. Exames realizados como eletrocardiograma,ecocardiograma e ressonância magnética, foram sugestivos de amiloidose cardíaca (AC) e aconfirmação feita através da biópsia cardíaca. Considerações finais: é importante oentendimento e o diagnóstico precoce da doença, a fim de melhorar a sobrevida do paciente

Case report: male patient of 62 years, hypertension, cardiac evaluation sought for surgical riskof varicectomia. Examinations performed as electrocardiography, echocardiography andmagnetic resonance were suggestive of cardiac amyloidosis and the confirmation made bycardiac biopsy. Conclusion: it is important to the understanding and early diagnosis of thedisease in order to improve patient survival.

Uso crônico e regular de estatina previne fibrilação atrial no pós-operatório de cirurgia cardíaca / Chronic and regular use of statin prevents atrial fibrillation in period after cardiac surgery

FUNDAMENTO: Fibrilação atrial é uma complicação frequente no pós-operatório de cirurgia cardíaca. O uso prévio de estatinas pode reduzir a incidência dessa arritmia. OBJETIVO: Avaliar se o uso crônico e regular de estatina, por um período de seis meses, previne fibrilação atrial no pós-operatório de cirurgia cardíaca eletiva. MÉTODOS: Estudo realizado em 107 pacientes submetidos à cirurgia cardíaca, 66 por cento do sexo masculino e com idade média de 60,4 anos (25 a 84). Avaliou-se a presença de fibrilação atrial entre os pacientes que usavam ou não estatina de forma regular no pré-operatório. Foram excluídos pacientes com cirurgia cardíaca de urgência, insuficiência renal, doenças inflamatórias, fibrilação atrial prévia, portadores de tireoidopatia e aqueles em uso de marca-passo definitivo. RESULTADOS: No período pós-operatório, fibrilação atrial esteve presente em 42 pacientes (39 por cento) da amostra, sendo 11 (26 por cento) em uso regular de estatina no período pré-operatório e 31 (74 por cento) não. Observou-se que, em 22 por cento do total de pacientes em uso de estatina, não houve desenvolvimento de fibrilação atrial, enquanto 45 por cento dos que não usavam estatina apresentaram arritmia (ρ=0,02). Na revascularização miocárdica isolada, 47 por cento dos pacientes que não usavam estatina e 23 por cento dos que usavam desenvolveram fibrilação atrial (ρ =0,02). Não houve diferença estatística significativa na análise dos grupos com ou sem estatina quanto à presença dos fatores de risco para desenvolvimento de fibrilação atrial ( ρ=0,34). CONCLUSÃO: O uso regular de estatina, por seis meses ou mais no período pré-operatório, reduziu a incidência de fibrilação atrial no pós-operatório de cirurgia cardíaca eletiva.

BACKGROND: Atrial fibrillation is a common complication after cardiac surgery. The previous use of statins may reduce the incidence of this arrhythmia. OBJECTIVE: To evaluate whether the chronic and regular use of statins, for a period of six months, prevents atrial fibrillation after elective cardiac surgery. METHODS: A study carried out with 107 patients that underwent cardiac surgery, including 66 percent of males and their mean age was 60.4 years (25 to 84). We evaluated the presence of atrial fibrillation among patients that used statins or not on a regular basis in the preoperative period. We excluded patients with urgent heart surgery, kidney failure, inflammatory diseases, previous atrial fibrillation, patients with thyroid disease and those using a permanent pacemaker. RESULTS: In the postoperative period, atrial fibrillation was present in 42 patients (39 percent) of the sample, including 11 (26 percent) people that had used statins on a regular basis in the preoperative period and 31 (74 percent) who had not. It was possible to observe that, in 22 percent of the patients that were using statin, there was no development of atrial fibrillation, while 45 percent of those who did not take statin had arrhythmia (ρ = 0.02). In the isolated myocardial revascularization, 47 percent of the patients that did not take statin and 23 percent of those that took statin developed atrial fibrillation ( ρ = 0.02). There was no statistically significant difference in the analysis of groups with or without statin for the presence of risk factors for the development of atrial fibrillation (ρ = 0.34). CONCLUSION: The regular use of statin, for six months or more in the preoperative period, reduced the incidence of atrial fibrillation after elective cardiac surgery.

Chronic and regular use of statin prevents atrial fibrillation in period after cardiac surgery.

BACKGROUND: [Corrected] Atrial fibrillation is a common complication after cardiac surgery. The previous use of statins may reduce the incidence of this arrhythmia. OBJECTIVE: To evaluate whether the chronic and regular use of statins, for a period of six months, prevents atrial fibrillation after elective cardiac surgery. METHODS: A study carried out with 107 patients that underwent cardiac surgery, including 66% of males and their mean age was 60.4 years (25 to 84). We evaluated the presence of atrial fibrillation among patients that used statins or not on a regular basis in the preoperative period. We excluded patients with urgent heart surgery, kidney failure, inflammatory diseases, previous atrial fibrillation, patients with thyroid disease and those using a permanent pacemaker. RESULTS: In the postoperative period, atrial fibrillation was present in 42 patients (39%) of the sample, including 11 (26%) people that had used statins on a regular basis in the preoperative period and 31 (74%) who had not. It was possible to observe that, in 22% of the patients that were using statin, there was no development of atrial fibrillation, while 45% of those who did not take statin had arrhythmia (ρ = 0.02). In the isolated myocardial revascularization, 47% of the patients that did not take statin and 23% of those that took statin developed atrial fibrillation ( ρ = 0.02). There was no statistically significant difference in the analysis of groups with or without statin for the presence of risk factors for the development of atrial fibrillation (ρ = 0.34). CONCLUSION: The regular use of statin, for six months or more in the preoperative period, reduced the incidence of atrial fibrillation after elective cardiac surgery.